Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...Find More
Dupilumab, a monoclonal antibody, is administered in the form of injection for the treatment of Atopic dermatitis (Eczema) in adults and children of age 12 and old. The injection works by hampering the substance in the body, which produces allergic reactions. Dupilumab is a receptor-antagonist and binds to the alph...Find More
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.